Bordonaro, R.
Ospedale Garibaldi
2 papers on CoChatORCID 0000-0001-5005-0880
Most cited papers
- Verified
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology
Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer
Cited by 116
- Verified
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa, L., Bozzarelli, S., Pietrantonio, F., Cordio, S., Lonardi, S., Toppo, L., Zaniboni, A., Bordonaro, R., Di Bartolomeo, M., Tomasello, G., et al. (2019) · Clinical Colorectal Cancer
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 50
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free